PHS
BCRX icon

PFM Health Sciences’s BioCryst Pharmaceuticals BCRX Stock Holding History

PFM Health Sciences’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-550,000
Closed -$5.82M – 88
2022
Q2 		$5.82M Buy
+550,000
New +$5.67M 0.22% 72

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PFM Health Sciences's BCRX Position: Q2 2026 in Review

PFM Health Sciences opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 207,357 shares worth $2.07M. The stake represents 0.18% of the portfolio and ranks #90 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in BCRX as recently as Q1 2023.

PFM Health Sciences first reported a position in BCRX in Q2 2021 and has held it in 6 quarters since. The position peaked at $27.2M in Q3 2022. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • PFM Health Sciences held 207,357 shares of BioCryst Pharmaceuticals worth $2.07M as of Q2 2026.
  • BioCryst Pharmaceuticals was a new PFM Health Sciences position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.18% of PFM Health Sciences's portfolio in Q2 2026, its #90 holding.
  • PFM Health Sciences first reported a position in BioCryst Pharmaceuticals in Q2 2021 and has held it in 6 quarters since.
  • PFM Health Sciences's BioCryst Pharmaceuticals position peaked at $27.2M in Q3 2022.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.